河北医学
河北醫學
하북의학
HEBEI MEDICINE
2015年
11期
1777-1779,1780
,共4页
陈冰%刘佳%李春东%张倩
陳冰%劉佳%李春東%張倩
진빙%류가%리춘동%장천
拉贝洛尔%妊娠期高血压%重度%分娩结局
拉貝洛爾%妊娠期高血壓%重度%分娩結跼
랍패락이%임신기고혈압%중도%분면결국
Labetalol%Gestational hypertension%Severe%Childbirth outcome
目的：探讨拉贝洛尔治疗重度妊娠期高血压临床效果及安全性，提高分娩质量。方法：选择50例患者随机分为观察组和对照组各25例，均给予常规治疗，对照组加用硝苯地平控释片，观察组加用拉贝洛尔，先静脉滴注，然后改为口服，观察组两组患者血压、24h尿蛋白含量、新生儿出生后1min及5min的Apgar评分、分娩结局。结果：治疗前，两组患者SBP、DBP 及24h尿蛋白含量相似，差异无统计学意义（ P＞0．05）；治疗1周后，两组SBP、DBP及24h尿蛋白含量较治疗前均明显下降，差异有统计学意义（ P＜0．05），但观察组SBP、DBP 及24h尿蛋白含量下降幅度明显大于对照组，差异有统计学意义（ P＜0．05）。观察组新生儿出生后1min及5min的Apgar评分均高于对照组，差异有统计学意义（ P＜0．05），观察组患者分娩结局明显优于对照组，差异有统计学意义（ P＜0．05）。结论：拉贝洛尔能有效控制重度妊娠期高血压、降低24h尿蛋白含量，临床疗效显著，显著改善母婴结局，值得临床推广应用。
目的：探討拉貝洛爾治療重度妊娠期高血壓臨床效果及安全性，提高分娩質量。方法：選擇50例患者隨機分為觀察組和對照組各25例，均給予常規治療，對照組加用硝苯地平控釋片，觀察組加用拉貝洛爾，先靜脈滴註，然後改為口服，觀察組兩組患者血壓、24h尿蛋白含量、新生兒齣生後1min及5min的Apgar評分、分娩結跼。結果：治療前，兩組患者SBP、DBP 及24h尿蛋白含量相似，差異無統計學意義（ P＞0．05）；治療1週後，兩組SBP、DBP及24h尿蛋白含量較治療前均明顯下降，差異有統計學意義（ P＜0．05），但觀察組SBP、DBP 及24h尿蛋白含量下降幅度明顯大于對照組，差異有統計學意義（ P＜0．05）。觀察組新生兒齣生後1min及5min的Apgar評分均高于對照組，差異有統計學意義（ P＜0．05），觀察組患者分娩結跼明顯優于對照組，差異有統計學意義（ P＜0．05）。結論：拉貝洛爾能有效控製重度妊娠期高血壓、降低24h尿蛋白含量，臨床療效顯著，顯著改善母嬰結跼，值得臨床推廣應用。
목적：탐토랍패락이치료중도임신기고혈압림상효과급안전성，제고분면질량。방법：선택50례환자수궤분위관찰조화대조조각25례，균급여상규치료，대조조가용초분지평공석편，관찰조가용랍패락이，선정맥적주，연후개위구복，관찰조량조환자혈압、24h뇨단백함량、신생인출생후1min급5min적Apgar평분、분면결국。결과：치료전，량조환자SBP、DBP 급24h뇨단백함량상사，차이무통계학의의（ P＞0．05）；치료1주후，량조SBP、DBP급24h뇨단백함량교치료전균명현하강，차이유통계학의의（ P＜0．05），단관찰조SBP、DBP 급24h뇨단백함량하강폭도명현대우대조조，차이유통계학의의（ P＜0．05）。관찰조신생인출생후1min급5min적Apgar평분균고우대조조，차이유통계학의의（ P＜0．05），관찰조환자분면결국명현우우대조조，차이유통계학의의（ P＜0．05）。결론：랍패락이능유효공제중도임신기고혈압、강저24h뇨단백함량，림상료효현저，현저개선모영결국，치득림상추엄응용。
Objective:To investigate the safety and clinical effects of labetalol in treatment of severe gestational hypertension , and to elevate the quality of childbirth .Method:A total of 50 patients were select-ed and randomly divided into observation group and control group , with 25 patients in each group .All the patients were given with conventional therapies , but the control group was given with nifedipine controlled-release tablets additionally , while the observation group given with labetalol additionally , intravenously dripped first, and then orally taken , and the blood pressures and 24h urine protein content of the patient ,Apgar scores at 1min and 5min after childbirth of the newborn , and childbirth outcomes of the two groups were observed.Result:Before the treatment, the two groups had similar SBP , DBP and 24h urine protein content, and the differences were statistically insignificant (P>0.05); at 1 week after the treatment, both groups had significantly decreased SBP , DBP and 24h urine protein content , and the differences were statis-tically significant ( P<0.05);but the observation group had significantly greater decreasing extents than the control group, and the differences were statistically significant (P<0.05).The newborns of the observation group had higher Apgar scores at 1min and 5min after childbirth than the control group , and the differences were statistically significant (P<0.05).The patients of the observation group had better childbirth outcomes than the control group , and the difference was statistically significant ( P<0.05) .Conclusion:Labetalol can effectively control severe gestational hypertension , decrease 24h urine protein content , and significantly im-prove childbirth outcome , has significant clinical therapeutic effects , and consequently is worthy of clinical application .
